Making the undruggable druggable
Unlocking challenging drug targets for the development of next-generation therapeutics
Selected Collaborations
It all starts with the drug target.
The majority of drug targets are so-called membrane proteins, and these are inherently unstable and challenging to investigate. Or so they were, until now.
Our proprietary Salipro® technology stabilizes membrane proteins in their native forms, enabling them to be employed in drug discovery programs for therapeutic antibodies or small molecule drugs. Through our in-house and partnered pipelines, we drive the discovery of novel drugs.
Pushing drug development forward together
We work with top-tier pharma and biotech partners to unlock drug targets for drug development programs.
Pipeline
We are driving forward drug development in our partnered as well as internal pipelines.
News
Salipro at BIO International Convention 2024
2024-05-17
Salipro Biotech will be attending this year's BIO International meeting in San Diego during June 3-6. Our BD Director Peter Jahnmatz and BD Manager Lorena Galán will be there to discuss drug development against challenging targets such as GPCRs, ion channels and transporters.
Connect with us via the partnering platform to set up a meeting!
Salipro Biotech and Bio-Rad Laboratories Inc. Present Novel CXCR4-Targeting Antibodies at PEGS Boston
2024-05-07
We're excited to announce the first results from our collaboration with Bio-Rad, leveraging our Salipro® platform with Bio-Rad’s Pioneer™ Antibody Discovery Platform.
This combination has yielded multiple novel human antibodies targeting wildtype CXCR4 with affinities similar to or exceeding ulocuplumab! These new CXCR4-targeting antibodies inhibit CXCL12 mediated cell migration similar or even better than ulocuplumab and offer the potential for enhanced efficacy and novel therapeutic avenues.
Join us at PEGS Boston to learn more about these exciting findings! We'll be delving deeper into the data at our Poster A080 and the presentation by Francisco Ylera (Bio-Rad) on Monday 13th at 2:45pm during the Display of Biologics session.
Salipro Biotech to present at Oxford Global Discovery Europe 2024
2024-04-30
Are you interested in DNA-Encoded Libraries (DEL) and planning to attend Oxford Global Discovery Europe 2024 on May 22-23 in Basel, Switzerland?
Then this is a great opportunity to join our CSO, Robin Löving, on May 22 when he will be sharing the latest advancements on the Salipro® technology for enabling small molecule drug discovery with DEL.
Make sure to hear Robin’s talk!
Oxford Global Discovery Europe link